TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11982617
Drug: Daclizumab 1
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1 mg/kg/dose every 14 d for five doses (Group I)
Study: 11982617
Drug: Daclizumab 2
Normalized name: daclizumab 25 MG per 5 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 2 mg/kg/dose every 14 d for two doses (Group II)
Study: 11982617
Drug: No antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibody induction (Group III)
Study: 2113567
Drug: Thyrotropin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin‐releasing hormone (TRH) (200 micrograms iv)
Study: 2113567
Drug: Apomorphine HCl
Normalized name: apomorphine HCl
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine HCl (Apo) (0.5 mg sc)
Study: 31124887
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg i.v. dexamethasone
Study: 27978548
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1200 mg elemental calcium)
Study: 23691925
Drug: Family group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family group psychotherapy (FGP) - 8 monthly sessions
Study: 17355744
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of valsartan (160 mg) and simvastatin (40 mg)
Study: 11517998
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) injections into the calf muscles
Study: 11517998
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injections (single blind control)
Study: 3262334
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin plus electric stimulation
Study: 29658856
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (pemetrexed and a platinum-based drug)
Study: 29658856
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (pemetrexed and a platinum-based drug)
Study: 25643246
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with intravenous narcotics
Study: 22998533
Drug: Flaxseed (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (40 g/day for 8 weeks)
Study: 9113256
Drug: m-chlorophenylpiperazine (m-CPP)
Normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-chlorophenylpiperazine (m-CPP) 0.5 mg/kg orally
Study: 4061896
Drug: Thiopental (2.5%)
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental (2.5%) administered at doses of 2, 3, 4, 5, 6, 7, or 8 mg/kg
Study: 31204610
Drug: Active peer
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active peer modeling intervention, including exercise prescription and information
Study: 29234038
Drug: Sodium tanshinone
Normalized name: Tanshinone I
DrugBank: Tanshinone I (DB16886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium tanshinone IIA sulfate (STS) injection (80 mg, once daily for 14 consecutive days)
Study: 23625305
Drug: Cornus mas
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cornus mas L. supplementation (50 g twice a day)
Study: 19212897
Drug: Self-initiated exercise
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Self-initiated exercise (no specific therapy recommended)
Study: 7081139
Drug: Bacillus Calmette‐Guerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette‐Guerin (BCG) adjuvant immunotherapy plus conventional therapy
Study: 6365474
Drug: Diprolene ointment
Normalized name: betamethasone Topical Ointment [Diprolene]
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diprolene ointment 0.05 percent (betamethasone dipropionate) applied topically at a fixed dose of 7 gm/day for 14 days (Study 1) or 21 days (Study 2)
Study: 6365474
Drug: Dermovate ointment
Normalized name: clobetasol Topical Ointment [Temovate]
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dermovate ointment 0.05 percent (clobetasone propionate) applied topically at a fixed dose of 7 gm/day for 14 days (Study 1) or 21 days (Study 2)
Study: 31296936
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 supplementation (50 µg per day)
Study: 22541245
Drug: Budesonide/formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI (320/9 μg twice-daily)
Study: 22541245
Drug: Budesonide pMDI
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide pMDI (320 μg twice-daily)
Study: 19548011
Drug: Oral‐B Professional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Professional Care 8500 (PC 8500)
Study: 19548011
Drug: Oral‐B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B CrossAction Vitalizer (CAV)
Study: 1524321
Drug: Continuous oscillation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oscillation therapy on the Kinetic Treatment Table
Study: 1524321
Drug: No continuous
Normalized name: Lotion, Multi Ingredient Topical application Lotion [AVEENO CONTINUOUS RADIANCE MOISTURIZING LOTION]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No continuous oscillation therapy (Control)
Study: 6360704
Drug: Fenoterol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.6 mg, pressurized aerosol)
Study: 6360704
Drug: Fenoterol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (1.0 mg, pressurized aerosol)
Study: 6360704
Drug: Fenoterol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.6 mg, dry powder)
Study: 6360704
Drug: Fenoterol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (1.0 mg, dry powder)
Study: 8557010
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg kg‐1 rocuronium (2 x ED95)
Study: 8557010
Drug: 0.06 mg
Normalized name: urea 0.06 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg kg‐1 priming dose followed by 0.24 mg kg‐1 rocuronium
Study: 7969680
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor treatment
Study: 31970939
Drug: TAC-302 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC-302 (100 to 1200 mg single dose)
Study: 31970939
Drug: TAC-302 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC-302 (400 mg single dose)
Study: 31970939
Drug: TAC-302 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC-302 (100, 200, or 400 mg multiple doses for 5 days, twice daily)
Study: 30838446
Drug: Lidocaine 40
Normalized name: lidocaine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 40 mg (Group L40)
Study: 30838446
Drug: Lidocaine 20
Normalized name: lidocaine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 20 mg (Group L20)
Study: 28817744
Drug: Oral voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral voriconazole (dosage not specified) and topical voriconazole, 1%
Study: 28817744
Drug: Topical natamycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical natamycin, 5% (added after 39 participants enrolled)
Study: 22836860
Drug: Intravenous somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous somatostatin
Study: 21071588
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BR) 0.5 l/day, containing ∼6.2 mmol of NO(3)(‐)
Study: 21071588
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) 0.5 l/day, containing ∼0.003 mmol of NO(3)(‐)
Study: 9062599
Drug: 0.5% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% lignocaine 1 mg/kg
Study: 9062599
Drug: 0.5% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% lignocaine 2 mg/kg
Study: 9062599
Drug: 0.5% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% lignocaine 2.89 mg/kg
Study: 8376436
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.5% bupivacaine injection into the wound (n = 30)
Study: 3740650
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 2 mg by inhalation
Study: 3740650
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 4 mg by inhalation
Study: 3740650
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 6 mg by inhalation
Study: 3740650
Drug: Atropine free
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine free base 1.67 mg by intramuscular injection
Study: 30547750
Drug: Intense treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense treatment (four two-weekly standard doses of praziquantel)
Study: 30547750
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (one standard dose of praziquantel)
Study: 26858331
Drug: CLND +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLND + High-Dose Interferon Alfa-2b (HDI)
Study: 15456336
Drug: Single-dose prulifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose prulifloxacin 600 mg
Study: 29130272
Drug: Formulary change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulary change (addition of a high-potency atorvastatin)
Study: 25601294
Drug: Exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure treatment in three contexts
Study: 25601294
Drug: Exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure treatment in one context
Study: 23392481
Drug: 3 rounds
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 rounds of annual mass drug administrations (MDAs) with azithromycin
Study: 8218682
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL immune serum globulin (ISG)
Study: 8218682
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL immune serum globulin (ISG)
Study: 3315600
Drug: Hospital administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital administration
Study: 3315600
Drug: At-home injection
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-home injection
Study: 21763099
Drug: Guideline-based drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based drug management
Study: 16039603
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy/Habit Reversal Training (ACT/HRT)
Study: 10773501
Drug: Droperidol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (2.5 mg) and fentanyl (0.4 mg) in 40 ml of 0.125% bupivacaine
Study: 10773501
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.4 mg fentanyl in 40 ml of 0.125% bupivacaine)
Study: 10773501
Drug: Butorphanol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (2 mg) and fentanyl (0.4 mg) in 40 ml of 0.125% bupivacaine
Study: 9053816
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg once-a-day
Study: 7953031
Drug: Home-based care
Normalized name: Gelato Home-Care 1.1 % Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based care (Daily Living Programme, DLP)
Study: 27905499
Drug: Brain-derived neurotrophic
Normalized name: brain-derived neurotrophic factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism treatment
Study: 22883658
Drug: Self-selected music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-selected music during initial radiotherapy treatment
Study: 22883658
Drug: No music
Approvals — FDA: no, EMA: no, PMDA: no
Description: No music during initial radiotherapy treatment (Control)
Study: 20550556
Drug: Continued pharmacotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued pharmacotherapy
Study: 15736890
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser alone (Group L: 10 pps, 200 mJ for 90 sec, n = 37)
Study: 15736890
Drug: Local minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local minocycline administration following laser treatment (Group LP, n = 33)
Study: 15736890
Drug: Povidone‐iodine irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone‐iodine irrigation following laser treatment (Group LI, n = 33)
Study: 1670585
Drug: Interferon-alpha (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (18 mu daily) and zidovudine (600 mg daily)
Study: 6617065
Drug: Propranolol 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 180 mg/day twice a day
Study: 6617065
Drug: Propranolol 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 180 mg/day three times a day
Study: 6617065
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing regimens (twice and three times a day)
Study: 29978322
Drug: r-batroxobin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-batroxobin (2.5 BU/2.0 mL)
Study: 29978322
Drug: r-batroxobin (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-batroxobin (5.0 BU/2.0 mL)
Study: 29978322
Drug: r-batroxobin (10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-batroxobin (10.0 BU/2.0 mL)
Study: 28531663
Drug: Ketogenic breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic breakfast intervention (50-250 ml medium-chain triglyceride drink + 5-15 g amino acids) after overnight fast during radiotherapy.
Study: 17447657
Drug: Antidiabetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic treatment with pioglitazone or glimepiride for 26 ± 2 weeks
Study: 11756064
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Zn/d for 14 d (Z group)
Study: 11756064
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup and placebo capsule (placebo group)
Study: 10483386
Drug: IAN/IO injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN/IO injection followed by repeated IO injection of 0.9 ml of 2% lidocaine with 1:100,000 epinephrine
Study: 10483386
Drug: IAN/IO injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAN/IO injection followed by mock IO injection
Study: 8074256
Drug: norfloxacin in
Normalized name: Product containing norfloxacin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfloxacin in a single 800‐mg dose
Study: 8074256
Drug: norfloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfloxacin, 400 mg twice a day for three days
Study: 8074256
Drug: trimethoprim (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim (160 mg)‐sulfamethoxazole (800 mg) (TMP‐SMX), twice a day for three days
Study: 8074256
Drug: trimethoprim (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim (160 mg)‐sulfamethoxazole (800 mg) (TMP‐SMX)
Study: 2530714
Drug: Sulotroban (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulotroban (4 x 800 mg per day)
Study: 196518
Drug: Sufentanil (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.025 mg/70 kg body weight)
Study: 196518
Drug: Fentanyl (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.25 mg/70 kg body weight)
Study: 30741684
Drug: LY2599666 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2599666 10 mg
Study: 30741684
Drug: LY2599666 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2599666 25 mg
Study: 30741684
Drug: LY2599666 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2599666 100 mg
Study: 30741684
Drug: LY2599666 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2599666 200 mg
Study: 30741684
Drug: LY2599666 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2599666 25 mg once-weekly for 12 weeks
Study: 19014837
Drug: LC15-0444 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC15-0444 (various doses 25, 50, 100, 200, 400, 600 mg)
Study: 9226432
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 2 mg zinc acetate
Study: 9226432
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 0.5 mg zinc acetate
Study: 9226432
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 0 mg zinc acetate
Study: 27729579
Drug: Enalapril 10-mg
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10-mg and folic acid 0.8-mg tablet
Study: 27729579
Drug: Enalapril 10-mg
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10-mg tablet alone
Study: 18773156
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/d) plus Ezetimibe (10 mg/d)
Study: 16182346
Drug: Individualized dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized dosage of 20 ml PCC based on target-INR of 2.1 or 1.5, initial-INR, and patient's body weight (group B)
Study: 16182346
Drug: Standard dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosage of 20 ml PCC equivalent to about 500 IU factor IX (group A)
Study: 10984002
Drug: Pramipexole (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (mean dose 0.70 mg/d, mean duration 24.4 weeks)
Study: 8791959
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g mesalazine in 30 mL (group I, n = 10)
Study: 8791959
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g mesalazine in 60 mL (group II, n = 12)
Study: 8791959
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g mesalazine in 100 mL (group III, n = 9)
Study: 1612319
Drug: Erythromycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (3 mg/kg) administered IV for 15 minutes
Study: 1612319
Drug: Saline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered IV for 15 minutes
Study: 6368353
Drug: Intensified conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified conventional insulin treatment (CIT)
Study: 29747810
Drug: Intense care
Normalized name: Glycerin 1.0 g in 45 g TOPICAL CREAM [TONYMOLY INTENSE CARE SNAIL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense care of oral hygiene (powered toothbrush and 1% chlorhexidine oral gel)
Study: 29747810
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care of oral hygiene (manual toothbrush and toothpaste)
Study: 26963601
Drug: Group Behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Behavioral Couples Therapy (G‐BCT) plus 12-step-oriented Individually Based Therapy (IBT)
Study: 26963601
Drug: Standard Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Behavioral Couples Therapy (S‐BCT) plus Individually Based Therapy (IBT)
Study: 18622068
Drug: Preemptive tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive tramadol (iv injection of tramadol 100 mg 15 min before operation)
Study: 18622068
Drug: Preventive tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive tramadol (same dose of tramadol 100 mg 15 min before the end of the operation)
Study: 7789488
Drug: Protriptyline 10
Normalized name: protriptyline 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protriptyline 10 mg daily
Study: 2141757
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g n-3 fatty acids
Study: 2141757
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g n-3 fatty acids
Study: 2141757
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g n-3 fatty acids
Study: 465277
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 12.5 mg and 25 mg
Study: 465277
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HCT and metoprolol
Study: 21899891
Drug: Kaltenborn manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaltenborn manual therapy
Study: 19132974
Drug: Topical glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glucocorticoids (GC)
Study: 16766330
Drug: Exomega milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exomega milk applied twice a day for 2 months
Study: 14722203
Drug: Infliximab plus
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab plus MTX (3 mg/kg or 10 mg/kg every 4 or 8 weeks)
Study: 9756005
Drug: Initial daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial daily administration of 6 million units of natural interferon-alpha subcutaneously for 2 weeks, then thrice a week for 22 weeks (Group A)
Study: 9756005
Drug: Thrice a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice a week administration of 6 million units of natural interferon-alpha for 26 weeks (Group B)
Study: 9756005
Drug: Initial daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial daily administration of interferon (Group A)
Study: 9756005
Drug: Thrice a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice a week administration of interferon (Group B)
Study: 9756005
Drug: Initial daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial daily administration of interferon (Group A) in patients with genotype 1b
Study: 9756005
Drug: Thrice a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice a week administration of interferon (Group B) in patients with genotype 1b